Losartan for Corneal Fibrosis
Topical Losartan as Treatment to Reduce Corneal Scarring Fibrosis
Universidad Autonoma de Nuevo Leon
46 participants
Feb 12, 2026
INTERVENTIONAL
Conditions
Summary
This is a prospective, randomized, double-blinded, controlled clinical trial designed to evaluate the efficacy and safety of topical losartan in improving visual acuity, contrast sensitivity and reducing corneal densitometry, corneal aberrations and corneal scarring severity in adult patients with corneal scars of different etiologies. Participants will be randomly assigned to receive either topical losartan 0.8 mg/mL or placebo eyedrops 6 times per day for six months.
Eligibility
Inclusion Criteria6
- Adults aged 18 years or older
- Presence of corneal scar with a duration of at least 1 month
- Corneal scars of any etiology
- Corneal scars with or without corneal neovascularization
- Stable corneal scar without epithelial defect
- No active treatment for the underlying condition for at least 1 month
Exclusion Criteria5
- Refusal or inability to provide written informed consent
- Presence of corneal epithelial defect or friable epithelium
- Age under 18 years
- Pregnancy
- Known allergy or hypersensitivity to losartan
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Drug: Topical Losartan 0.8 mg/ml ophthalmic solution, one drop applied six times daily for six months.
Drug: Balanced saline solution ophthalmic drops, one drop applied six times daily for six months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07449000